m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05923
 [1]
Non-coding RNA circRHBDD1 IGF2BP2  lncRNA       miRNA   circRNA Direct Enhancement m6A modification CD274 CD274 IGF2BP2 : m6A sites
m6A Modification:
m6A Regulator Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) READER
 Regulator Info 
m6A Target Programmed cell death 1 ligand 1 (CD274/PD-L1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator hsa_circ_0058493 (Circ_RHBDD1) circRNA View Details
Regulated Target Insulin like growth factor 2 mRNA binding protein 2 (IGF2BP2) View Details
Crosstalk Relationship ncRNA  →  m6A Enhancement
Crosstalk Mechanism ncRNAs directly impacts m6A modification through recruiting m6A regulator
Crosstalk Summary Circ_RHBDD1 binds to IGF2BP2, disrupting the interaction between E3 ligase TRIM25 and IGF2BP2, and ultimately inhibiting IGF2BP2 ubiquitination and degradation. Intriguingly, IGF2BP2 enhances Programmed cell death 1 ligand 1 (CD274/PD-L1) mRNA stability through m6A modification.
Responsed Disease Gastric cancer ICD-11: 2B72
 Disease Info 
Cell Process Immune Evasion
In-vitro Model
 MKN28 Gastric tubular adenocarcinoma Homo sapiens CVCL_1416
In-vivo Model C57BL/6 mice (6-8 weeks old, female) were used to create tumor models by subcutaneous injection of GC cells. When tumors reached ~ 100 mm3, mice were injected with PLGA-PEG(si-circRHBDD1) NPs or PLGA-PEG(siRNA control) NPs (200 mg/kg) via tail vein.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
CD274 molecule (CD274) 55 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Avelumab Approved [2]
External Link
TTD: D0K7SX
 Compound Name Durvalumab Approved [3]
MOA Modulator
External Link
TTD: D0LS9E
 Compound Name RG-7446 Approved [4]
External Link
TTD: D0OZ4J
 Compound Name Bavencio Approved [5]
MOA Inhibitor
External Link
TTD: D0W8HN
 Compound Name Atezolizumab Approved [6]
External Link
TTD: D0YM2K
 Compound Name Sugemalimab Approved in China [7]
External Link
TTD: DDZ48Y
 Compound Name MEDI4736 Phase 3 [8]
MOA Modulator
External Link
TTD: D04RRZ
 Compound Name MPDL-3280A Phase 3 [9]
MOA Modulator
External Link
TTD: D0Y5IH
 Compound Name CS1001 Phase 3 [10]
External Link
TTD: D3MP1S
 Compound Name A167 Phase 3 [11]
Synonyms
KL-A167
    Click to Show/Hide
External Link
TTD: DI89WD
 Compound Name KN046 Phase 3 [12]
MOA Inhibitor
External Link
TTD: DLOQ25
 Compound Name Pidilizumab Phase 2 [13]
Synonyms
CT-011
    Click to Show/Hide
External Link
TTD: D09MRL
 Compound Name KN035 Phase 2 [14]
Synonyms
Envafolimab
    Click to Show/Hide
External Link
TTD: D0GF2R
 Compound Name CX-072 Phase 2 [15]
MOA Inhibitor
External Link
TTD: D0Z2BO
 Compound Name INCB86550 Phase 2 [16]
MOA Inhibitor
External Link
TTD: DKM79E
 Compound Name Bintrafusp alfa Phase 2 [17]
External Link
TTD: D5J3BL
 Compound Name M7824 Phase 2 [18]
MOA Inhibitor
External Link
TTD: D05FPZ
 Compound Name BGB-A333 Phase 1/2 [19]
External Link
TTD: DC5VW9
 Compound Name GS-4224 Phase 1/2 [20]
Synonyms
Methyl Pyridazine-4-carboxylate; 34231-77-1; PYRIDAZINE-4-CARBOXYLIC ACID METHYL ESTER; 4-PYRIDAZINECARBOXYLIC ACID, METHYL ESTER; MFCD09953488; ACMC-1AJNN; methyl 4-pyridazinecarboxylate; methylpyridazine-4-carboxylate; SCHEMBL1421640; DTXSID30498310; AMY24958; BCP22435; ANW-50355; ZINC12359421; AKOS015854403; Methyl pyridazine-4-carboxylate, 97%; AC-4414; CS-W003697; PB31452; 4-Pyridazinecarboxylic acid methyl ester; AK-48857; SY004472; AB0024323; DB-030309; FT-0717698; W5569; S-2990; J-522632
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 12439252
TTD: DS6VD0
 Compound Name NM21-1480 Phase 1/2 [21]
MOA Modulator
External Link
TTD: DUVH60
 Compound Name LY3300054 Phase 1 [18]
External Link
TTD: D08HSS
 Compound Name MSB2311 Phase 1 [14]
External Link
TTD: D0A8AU
 Compound Name Anti-PD-L1 Phase 1 [22]
Synonyms
BMS-936559
    Click to Show/Hide
External Link
TTD: D0KP9A
 Compound Name FAZ053 Phase 1 [15]
MOA Inhibitor
External Link
TTD: D0LU1O
 Compound Name Anti-PD-L1 CSR T cells Phase 1 [23]
MOA CAR-T-Cell-Therapy
External Link
TTD: D0W7UD
 Compound Name BMS-986189 Phase 1 [14]
MOA Inhibitor
External Link
TTD: D0X1GN
 Compound Name Cosibelimab Phase 1 [24]
Synonyms
CK-301/TG-1501
    Click to Show/Hide
External Link
TTD: D17URP
 Compound Name CA-170 Phase 1 [25]
MOA Inhibitor
External Link
TTD: D2Z6WF
 Compound Name PD-L1 t-haNK Phase 1 [26]
External Link
TTD: DH42RF
 Compound Name KD033 Phase 1 [27]
MOA Inhibitor
External Link
TTD: DJVR06
 Compound Name C-Met/PD-L1 CAR-T Cell Phase 1 [28]
MOA CAR-T-Cell-Therapy(Dual specific)
External Link
TTD: D03GTO
 Compound Name CA-170 Phase 1 [18]
Synonyms
3-Aminopyrrolidine dihydrochloride; 103831-11-4; pyrrolidin-3-amine dihydrochloride; 3-Pyrrolidinamine, dihydrochloride; 3-Aminopyrrolidine 2HCl; 3-Aminopyrrolidine diHCl; SCHEMBL555933; ACMC-2099s1; ACMC-2099s3; ACMC-20989g; 3-pyrrolidinamine dihydrochloride; CTK0H7226; DTXSID00583661; MolPort-002-343-989; NJPNCMOUEXEGBL-UHFFFAOYSA-N; 3-Amino-pyrrolidine dihydrochloride; KS-00000JI6; ACT01710; ANW-14978; SBB003982; ( -3-Aminopyrrolidine dihydrochloride; AKOS015844825; VP60158; AM85320; VP60228; TRA0055207; TRA0000843; TRA0097
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 16212596
TTD: D09PPU
 Compound Name FS118 Phase 1 [14]
External Link
TTD: D0XO9F
 Compound Name PF-07257876 Phase 1 [29]
External Link
TTD: D1A7OP
 Compound Name MCLA-145 Phase 1 [30]
MOA Agonist
External Link
TTD: D2QY0Z
 Compound Name GEN1046 Phase 1 [31]
MOA Agonist
External Link
TTD: D3HBJ1
 Compound Name ALPN-202 Phase 1 [32]
MOA Inhibitor
External Link
TTD: D82UVG
 Compound Name TAK-252 Phase 1 [33]
Synonyms
SL-279252
    Click to Show/Hide
MOA Agonist
External Link
TTD: D9SL1N
 Compound Name INBRX-105 Phase 1 [34]
MOA Inhibitor
External Link
TTD: DA1X5W
 Compound Name LY3415244 Phase 1 [35]
MOA Inhibitor
External Link
TTD: DC8HR6
 Compound Name A337 Phase 1 [11]
External Link
TTD: DL97UQ
 Compound Name IBI318 Phase 1 [36]
MOA Inhibitor
External Link
TTD: DX30BA
 Compound Name PMID30107136-Compound-Example2 Patented [37]
MOA Inhibitor
Activity IC50 = 150 nM
External Link
CID: 117941742
TTD: D0OK1S
 Compound Name PMID30107136-Compound-Example1 Patented [37]
MOA Inhibitor
Activity IC50 = 18 nM
External Link
CID: 117951478
TTD: D0WQ9X
 Compound Name PMID30247903-Compound-General structure7 Investigative [14]
Synonyms
PMID30247903Compound7
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D01TGF
 Compound Name CA-327 Investigative [14]
MOA Inhibitor
External Link
TTD: D04ILU
 Compound Name PMID30247903-Compound-General structure8 Investigative [14]
Synonyms
PMID30247903Compound8
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D04QGF
 Compound Name PMID30247903-Compound-General structure5 Investigative [14]
Synonyms
PMID30247903Compound5
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D07BOF
 Compound Name PMID30247903-Compound-General structure12 Investigative [14]
Synonyms
PMID30247903Compound12
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D09BYN
 Compound Name PMID30247903-Compound-General structure9 Investigative [14]
Synonyms
PMID30247903Compound9
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0GG6N
 Compound Name PMID30247903-Compound-General structure6 Investigative [14]
Synonyms
PMID30247903Compound6
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0TN4F
 Compound Name PMID30247903-Compound-General structure10 Investigative [14]
Synonyms
PMID30247903Compound10
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0XL3N
 Compound Name YH011 Investigative [38]
External Link
TTD: DA91UG
 Compound Name YH010 Investigative [39]
External Link
TTD: DBTI39
 Compound Name RG6084 Phase 1 [40]
External Link
TTD: DJX7K9
2B72: Gastric cancer 81 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Leniolisib Approved [41]
Synonyms
1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ
    Click to Show/Hide
External Link
CID: 57495353
TTD: DGO2C1
 Compound Name Atezolizumab Approved [18]
External Link
TTD: D0YM2K
 Compound Name Bavencio Approved [18]
External Link
TTD: D0W8HN
 Compound Name Tebentafusp Approved [42]
External Link
TTD: D0S0BJ
 Compound Name Merimepodib Approved [43]
Synonyms
Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid
    Click to Show/Hide
External Link
CID: 153241
TTD: D0F0ZE
DrugBank: DB04862
 Compound Name Taxol Approved [44]
Synonyms
C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-
    Click to Show/Hide
External Link
CID: 36314
TTD: D0C4RB
DrugBank: DB01229
 Compound Name Ramucirumab Approved [45]
Synonyms
LY3009806
    Click to Show/Hide
External Link
TTD: D09HVD
 Compound Name Tucatinib Approved [46]
Synonyms
Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE
    Click to Show/Hide
External Link
CID: 51039094
TTD: D09GRX
DrugBank: DB11652
 Compound Name Antacids Approved [47]
External Link
TTD: D06AJL
 Compound Name Trastuzumab Approved [18]
Synonyms
Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)
    Click to Show/Hide
External Link
TTD: D04WFL
 Compound Name Carbamazepine Phase 3 [48]
Synonyms
Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals
    Click to Show/Hide
External Link
CID: 2554
TTD: D04MSM
DrugBank: DB00564
 Compound Name Margetuximab Approved [18]
External Link
TTD: D01YYP
 Compound Name Nivolumab Approved [18]
External Link
TTD: D00GOV
 Compound Name GRANITE Phase 3 [49]
Synonyms
Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-
    Click to Show/Hide
External Link
CID: 11784975
TTD: DKF9I3
 Compound Name Zolbetuximab Phase 3 [50]
Synonyms
IMAB362
    Click to Show/Hide
External Link
TTD: D4HQ1F
 Compound Name Tusamitamab ravtansine Phase 3 [51]
Synonyms
SAR408701
    Click to Show/Hide
External Link
TTD: D2D6NJ
 Compound Name Andecaliximab Phase 3 [52]
External Link
TTD: D0Z6SP
 Compound Name ABP 980 Phase 3 [15]
External Link
TTD: D0WZ0X
 Compound Name GS-5745 Phase 3 [44]
External Link
CID: 56776542
TTD: D0WL0Q
 Compound Name S-1 Phase 3 [53]
Synonyms
Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)
    Click to Show/Hide
External Link
CID: 163872
TTD: D0S8LJ
 Compound Name Lonsurf Phase 3 [18]
External Link
TTD: D0PM0Y
 Compound Name GDC-0068 Phase 3 [44]
Synonyms
RG7440
    Click to Show/Hide
External Link
CID: 24788740
TTD: D0I4TH
DrugBank: DB11743
 Compound Name Edotecarin Phase 3 [54]
Synonyms
ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione
    Click to Show/Hide
External Link
CID: 9808998
TTD: D0I1DW
DrugBank: DB04882
 Compound Name RG3638 Phase 3 [55]
Synonyms
Onartuzumab
    Click to Show/Hide
External Link
TTD: D0H9PT
 Compound Name G17DT Phase 3 [56]
Synonyms
Gastrimmune; Insegia
    Click to Show/Hide
External Link
TTD: D0G8ZQ
 Compound Name DE-766 Phase 3 [57]
External Link
TTD: D0FJ1W
 Compound Name Tesetaxel Phase 2 [58]
Synonyms
DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE
    Click to Show/Hide
External Link
CID: 6918574
TTD: D0F9VH
DrugBank: DB12019
 Compound Name Nelipepimut S Phase 3 [59]
Synonyms
E75
    Click to Show/Hide
External Link
CID: 9941306
TTD: D0F8UV
 Compound Name BMS-986205 Phase 3 [18]
Synonyms
KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-
    Click to Show/Hide
External Link
CID: 121328278
TTD: D0DP5I
DrugBank: DB14986
 Compound Name Rivoceranib Phase 3 [18]
External Link
TTD: D0D7BX
 Compound Name Claudiximab Phase 3 [18]
Synonyms
IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed
    Click to Show/Hide
External Link
TTD: D0B3ZC
 Compound Name OS-440 Phase 3 [60]
Synonyms
CNS modulator (spasticity), Osmotica
    Click to Show/Hide
External Link
TTD: D09OHH
 Compound Name Oraxol Phase 3 [18]
External Link
TTD: D04UWU
 Compound Name ICI 118,551 Phase 3 [44]
Synonyms
Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO
    Click to Show/Hide
External Link
CID: 3682
TTD: D04DJS
 Compound Name Evorpacept Phase 2/3 [61]
Synonyms
ALX148
    Click to Show/Hide
External Link
TTD: DRP8H0
 Compound Name BNT141 Phase 2 [62]
External Link
TTD: DFZ19J
 Compound Name Anti-LAG3 Phase 2 [15]
External Link
TTD: D0T7OI
 Compound Name GSK1292263 Phase 2 [63]
External Link
CID: 24996872
TTD: D0S4II
DrugBank: DB12627
 Compound Name MM-111 Phase 2 [64]
External Link
TTD: D0Q2KM
 Compound Name Plevitrexed Phase 2 [65]
Synonyms
ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,
    Click to Show/Hide
External Link
CID: 135430970
TTD: D0I9GR
DrugBank: DB06163
 Compound Name DS-8201 Phase 1 [15]
Synonyms
9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-
    Click to Show/Hide
External Link
CID: 10671
TTD: D0E8IQ
 Compound Name XL880 Phase 2 [66]
Synonyms
GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors
    Click to Show/Hide
External Link
CID: 42642645
TTD: D0D1GF
DrugBank: DB12307
 Compound Name Matuzumab Phase 2 [67]
Synonyms
EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals
    Click to Show/Hide
External Link
TTD: D0BZ7V
 Compound Name BAY-57-9352 Phase 2 [44]
Synonyms
Telatinib; Bay 57-9352
    Click to Show/Hide
External Link
CID: 9808844
TTD: D07NOI
DrugBank: DB15393
 Compound Name Bemarituzumab Phase 2 [68]
External Link
TTD: D05ISO
 Compound Name PEGPH20 Phase 2 [18]
External Link
TTD: D05INV
 Compound Name Plevitrexed (R)-isomer Phase 2 [69]
Synonyms
YW3548
    Click to Show/Hide
External Link
CID: 213022
TTD: D04FYZ
 Compound Name APR-246 Phase 2 [70]
Synonyms
Eprenetapopt
    Click to Show/Hide
External Link
CID: 52918385
TTD: D03XTY
DrugBank: DB11684
 Compound Name CRS-207 Phase 2 [59]
External Link
TTD: D02WSB
 Compound Name Opdivo + Yervoy Phase 3 [18]
External Link
TTD: D02VYE
 Compound Name CT-041 Phase 1/2 [71]
External Link
TTD: DJ6AW5
 Compound Name BPX-601 Phase 1/2 [72]
External Link
TTD: D0TY6U
 Compound Name Anti-MUC1 CAR-T cells Phase 1/2 [73]
External Link
TTD: D0C9MJ
 Compound Name Anti-Mesothelin CAR-T cells Phase 1/2 [74]
External Link
TTD: D0BE6M
 Compound Name Anti-HER2 CAR-T Phase 1/2 [75]
External Link
TTD: D08QZH
 Compound Name CAR-T Cells targeting EpCAM Phase 1/2 [76]
External Link
TTD: D08QYW
 Compound Name PAT-SC1 Phase 1/2 [77]
Synonyms
SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab
    Click to Show/Hide
External Link
TTD: D00UOQ
 Compound Name ASP2138 Phase 1 [78]
External Link
TTD: DTQL30
 Compound Name SAR443216 Phase 1 [79]
External Link
TTD: DL6F3E
 Compound Name AMG 199 Phase 1 [80]
External Link
TTD: DEP3Z8
 Compound Name AMG 910 Phase 1 [81]
External Link
TTD: DEDP81
 Compound Name Alofanib Phase 1 [82]
Synonyms
1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid
    Click to Show/Hide
External Link
CID: 86280646
TTD: D47MOS
 Compound Name HER2-specific CAR T cell Phase 1 [83]
External Link
TTD: D0YF6K
 Compound Name Anti-CEA-CAR T Phase 1 [84]
External Link
TTD: D0S1QN
 Compound Name XR-5944 Phase 1 [85]
Synonyms
MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942
    Click to Show/Hide
External Link
CID: 439035
TTD: D0Q5TH
DrugBank: DB06364
 Compound Name A168 Phase 1 [11]
External Link
TTD: D0L9PU
 Compound Name EGFR806-specific CAR T cell Phase 1 [86]
External Link
TTD: D0I7ZH
 Compound Name AbGn-107 Phase 1 [18]
External Link
TTD: D08GZE
 Compound Name FPA144 Phase 1 [15]
External Link
TTD: D06NND
 Compound Name Minnelide 001 Phase 1 [44]
External Link
TTD: D05UFJ
 Compound Name CAR-T cells targeting EpCAM Phase 1 [87]
External Link
TTD: D01TNK
 Compound Name Anti-CEA CAR-T cells Phase 1 [88]
External Link
TTD: D00KDQ
 Compound Name EPCAM-targeted CAR-T cells Clinical trial [89]
External Link
TTD: D0T8DD
 Compound Name PMID28460551-Compound-1 Patented [90]
External Link
CID: 25190990
TTD: D0IH3I
DrugBank: DB14866
 Compound Name Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1 Patented [91]
Synonyms
PMID28621580-Compound-WO2012084683c62
    Click to Show/Hide
External Link
TTD: D04PKQ
 Compound Name TOPIXANTRONE HYDROCHLORIDE Discontinued in Phase 2 [92]
Synonyms
SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride
    Click to Show/Hide
External Link
CID: 6918273
TTD: D06DWQ
 Compound Name MDL 101,731 Discontinued in Phase 2 [93]
Synonyms
Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331
    Click to Show/Hide
External Link
CID: 6435808
TTD: D05HZI
DrugBank: DB06433
 Compound Name BBR-3438 Discontinued in Phase 2 [94]
Synonyms
Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438
    Click to Show/Hide
External Link
CID: 3038512
TTD: D01VPR
 Compound Name IPI-493 Discontinued in Phase 1 [95]
Synonyms
[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851
    Click to Show/Hide
External Link
CID: 9893658
TTD: D0BM6S
DrugBank: DB13023
 Compound Name Kanjinti Application submitted [18]
External Link
TTD: D0CW3U
 Compound Name Anti-CD9 mab Investigative [96]
Synonyms
ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University
    Click to Show/Hide
External Link
TTD: D09BPT
References
Ref 1 CircRHBDD1 promotes immune escape via IGF2BP2/PD-L1 signaling and acts as a nanotherapeutic target in gastric cancer. J Transl Med. 2024 Jul 30;22(1):704. doi: 10.1186/s12967-024-05498-9.
Ref 2 Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015 Oct;3(10):1148-1157. doi: 10.1158/2326-6066.CIR-15-0059. Epub 2015 May 26.
Ref 3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
Ref 4 PD-1 as a potential target in cancer therapy. Cancer Med. 2013 October; 2(5): 662-673.
Ref 5 ClinicalTrials.gov (NCT03403777) Avelumab in Refractory Testicular Germ Cell Cancer.. U.S. National Institutes of Health.
Ref 6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
Ref 7 Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599.
Ref 8 National Cancer Institute Drug Dictionary (drug id 740856).
Ref 9 Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol. 2014 May 10; 5(2): 39-47.
Ref 10 GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Transl Lung Cancer Res. 2020 Oct;9(5):2008-2015. doi: 10.21037/tlcr-20-608.
Ref 11 Clinical pipeline report, company report or official report of Klus Pharma
Ref 12 Clinical pipeline report, company report or official report of Alphamab Oncology.
Ref 13 PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother. 2011 Jun;34(5):409-18. doi: 10.1097/CJI.0b013e31821ca6ce.
Ref 14 Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
Ref 15 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 16 National Cancer Institute Drug Dictionary (drug name INCB086550).
Ref 17 Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-Beta and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. J Thorac Oncol. 2020 Jul;15(7):1210-1222. doi: 10.1016/j.jtho.2020.03.003. Epub 2020 Mar 13.
Ref 18 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 19 Clinical pipeline report, company report or official report of BeiGene.
Ref 20 Clinical pipeline report, company report or official report of Gilead Sciences.
Ref 21 Clinical pipeline report, company report or official report of Numab Therapeutics.
Ref 22 Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 28;366(26):2455-65. doi: 10.1056/NEJMoa1200694. Epub 2012 Jun 2.
Ref 23 ClinicalTrials.gov (NCT02937844) Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme
Ref 24 Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Ref 25 CA-170 - A Potent Small-Molecule PD-L1 Inhibitor or Not?. Molecules. 2019 Aug 1;24(15):2804. doi: 10.3390/molecules24152804.
Ref 26 ClinicalTrials.gov (NCT04050709) QUILT 3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers. U.S. National Institutes of Health.
Ref 27 Clinical pipeline report, company report or official report of Kadmon.
Ref 28 ClinicalTrials.gov (NCT03672305) Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC
Ref 29 ClinicalTrials.gov (NCT04881045) A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07257876 IN PATIENTS WITH ADVANCED OR METASTATIC TUMORS. U.S.National Institutes of Health.
Ref 30 Clinical pipeline report, company report or official report of Merus.
Ref 31 Clinical pipeline report, company report or official report of Genmab.
Ref 32 Clinical pipeline report, company report or official report of Alpine Immune Sciences.
Ref 33 Clinical pipeline report, company report or official report of Shattuck Labs.
Ref 34 Clinical pipeline report, company report or official report of Inhibrx.
Ref 35 Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors. Clin Cancer Res. 2021 May 15;27(10):2773-2781. doi: 10.1158/1078-0432.CCR-20-3716. Epub 2021 Jan 13.
Ref 36 Clinical pipeline report, company report or official report of Innovent.
Ref 37 A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018). Expert Opin Ther Pat. 2018 Sep;28(9):665-678. doi: 10.1080/13543776.2018.1512706. Epub 2018 Sep 10.
Ref 38 Clinical pipeline report, company report or official report of Biocytogen
Ref 39 Clinical pipeline report, company report or official report of Biocytogen
Ref 40 TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751.
Ref 41 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217759.
Ref 42 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761228.
Ref 43 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022059.
Ref 44 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 45 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7390).
Ref 46 ClinicalTrials.gov (NCT04499924) Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer (MOUNTAINEER-02). U.S. National Institutes of Health.
Ref 47 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 48 ClinicalTrials.gov (NCT01128959) Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy. U.S. National Institutes of Health.
Ref 49 ClinicalTrials.gov (NCT00879333) Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC) (GRANITE-1). U.S. National Institutes of Health.
Ref 50 ClinicalTrials.gov (NCT03504397) A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight). U.S. National Institutes of Health.
Ref 51 ClinicalTrials.gov (NCT05703555) INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701. U.S.National Institutes of Health.
Ref 52 ClinicalTrials.gov (NCT02545504) Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (GAMMA-1). U.S. National Institutes of Health.
Ref 53 Clinical pipeline report, company report or official report of Taiho Pharma U.S.A.
Ref 54 Edotecarin: a novel topoisomerase I inhibitor. Clin Colorectal Cancer. 2005 May;5(1):27-36.
Ref 55 ClinicalTrials.gov (NCT02488330) An Extension Study of Onartuzumab in Patients With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study.
Ref 56 ClinicalTrials.gov (NCT02118077) Sequential Trial of G17DT for the Treatment of Advanced Pancreatic Cancer. U.S. National Institutes of Health.
Ref 57 Clinical pipeline report, company report or official report of Daiichi Sankyo.
Ref 58 ClinicalTrials.gov (NCT01221870) Tesetaxel as First-line Therapy for Metastatic Breast Cancer. U.S. National Institutes of Health.
Ref 59 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 60 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031678)
Ref 61 ClinicalTrials.gov (NCT05002127) A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06). U.S.National Institutes of Health.
Ref 62 ClinicalTrials.gov (NCT04683939) Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT141 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With CLDN18.2-positive Solid Tumors. U.S.National Institutes of Health.
Ref 63 ClinicalTrials.gov (NCT01218204) A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin.U.S. National Institutes of Health.
Ref 64 ClinicalTrials.gov (NCT01774851) A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach. U.S. National Institutes of Health.
Ref 65 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8278).
Ref 66 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5679).
Ref 67 ClinicalTrials.gov (NCT00073541) A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer. U.S. National Institutes of Health.
Ref 68 ClinicalTrials.gov (NCT03694522) A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT) (FIGHT). U.S. National Institutes of Health.
Ref 69 Clinical pipeline report, company report or official report of plevitrexed.
Ref 70 ClinicalTrials.gov (NCT04383938) Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies. U.S. National Institutes of Health.
Ref 71 ClinicalTrials.gov (NCT04404595) Open-label, Multicenter, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous Anti-claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Subjects With Advanced Gastric, Pancreatic, or Other Specified Digestive System Cancers. U.S.National Institutes of Health.
Ref 72 ClinicalTrials.gov (NCT02744287) Use of Ligand-Inducible Autologous T Cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors
Ref 73 ClinicalTrials.gov (NCT02617134) CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor
Ref 74 ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Ref 75 ClinicalTrials.gov (NCT02713984) A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
Ref 76 ClinicalTrials.gov (NCT03013712) A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer
Ref 77 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013314)
Ref 78 ClinicalTrials.gov (NCT05365581) A Phase 1/1b Study of ASP2138 in Participants With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression. U.S.National Institutes of Health.
Ref 79 Clinical pipeline report, company report or official report of Sanofi
Ref 80 ClinicalTrials.gov (NCT04117958) Study of AMG 199 in Subjects With MUC17-Positive Gastric and Gastroesophageal Junction Cancer. U.S. National Institutes of Health.
Ref 81 ClinicalTrials.gov (NCT04260191) Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma. U.S. National Institutes of Health.
Ref 82 ClinicalTrials.gov (NCT04071184) Study of Alofanib in Patients With Metastatic Gastric Cancer. U.S. National Institutes of Health.
Ref 83 ClinicalTrials.gov (NCT03500991) HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
Ref 84 ClinicalTrials.gov (NCT02349724) A Clinical Research of CAR T Cells Targeting CEA Positive Cancer
Ref 85 Antitumor activity of XR5944, a novel and potent topoisomerase poison. Anticancer Drugs. 2001 Apr;12(4):359-67.
Ref 86 ClinicalTrials.gov (NCT03638167) EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
Ref 87 ClinicalTrials.gov (NCT03563326) Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART)
Ref 88 ClinicalTrials.gov (NCT03682744) CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
Ref 89 ClinicalTrials.gov (NCT02725125) Study Evaluating the Efficacy and Safety With CAR-T for Stomach Cancer
Ref 90 Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015). Expert Opin Ther Pat. 2017 Jul;27(7):753-761. doi: 10.1080/13543776.2017.1325465. Epub 2017 May 5.
Ref 91 VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016). Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. doi: 10.1080/13543776.2017.1344215. Epub 2017 Jun 23.
Ref 92 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015071)
Ref 93 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002544)
Ref 94 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007244)
Ref 95 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026781)
Ref 96 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.